Advertisement

Topics

High Costs of FDA Approval for Formerly Unapproved Marketed Drugs

19:00 EST 12 Nov 2017 | JAMA

This Viewpoint describes how the US Food and Drug Administration’s 2006 Unapproved Drugs Initiative may have unintentionally made generic drugs more expensive and inaccessible and proposes policy reforms to address the harms of those price increases.

Original Article: High Costs of FDA Approval for Formerly Unapproved Marketed Drugs

NEXT ARTICLE

More From BioPortfolio on "High Costs of FDA Approval for Formerly Unapproved Marketed Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...